Cour Pharmaceuticals Development Co., Inc. Email Format
Biotechnology ResearchIllinois, United States51-200 Employees
COUR is a clinical-stage biotechnology company working to reprogram the immune system to restore health in people suffering from autoimmune diseases. Using our proprietary COUR nanoparticle (CNP) platform for antigen-specific immune tolerance, we develop first-in-class disease-modifying therapies that target disease at its root—without suppressing normal immune system function. With programs in primary biliary cholangitis (PBC), type 1 diabetes (T1D), myasthenia gravis (MG), and celiac disease, COUR is advancing a new standard for immune-modifying therapies.